The Form 4 filing, a report of an insider's stock trades, is dated Nov. 17, 2026. The sales took place on Nov. 13. Heeson Lee serves as executive vice president and head of Incyte International.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-13 |
| Date of Latest Transaction | 2026-11-13 |
| Buy/Sell | sell |
| Transaction Count | 5 |
| Shares Transacted | 10,694 |
| Price | $120.82 |
| Total Transaction Value | $1,292,031.93 |
| Insider | |
| Ticker Symbol | INCY |
| Company | INCYTE CORP |
| Insider Name | Heeson Lee |
| Insider Title | EVP, Head of Incyte Intl |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 26,884 |
| Position Size Change | 28.46% |
| Filing | |
| Filing Date | 2026-11-17 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of Incyte (INCY) shares, reported under transaction code S. They cover five transactions by Heeson Lee in one filing.
What was the average price of the transaction?
The average sale price was $120.82 per share, rounded to cents. This average covers the five reported sales. Separate prices for those sales were not provided.
How did this transaction affect the insider's holdings?
After selling 10,694 shares, Heeson Lee reported owning 26,884 shares. The shares sold made up 28.46% of the shares owned before the sales.
What's the total transaction value?
The total value was $1,292,031.93 for all five sales, rounded to cents. This amount covers the full 10,694 shares reported as sold.
Are there any special circumstances around this transaction?
The available details note a Rule 10b5-1 plan reference. These plans set trading instructions in advance. Without footnote text, it is unclear which of the five sales the reference covers. The plan's start date and trading schedule are unknown.
For research purposes only; not investment advice.